AYArsheena Yassin

Arsheena Yassin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arsheena Yassin has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful desensitization to liposomal amphotericin B for the treatment of disseminated cryptococcosis in pregnancy: a case report

    by Susanne O. Ajao, Julia M. Nelson, Arsheena Yassin, Emily B. Rosenfeld, Justin S. Brandt, Catherine Monteleone, Pinki J. Bhatt, Ahmed Abdul Azim

    Background: Cryptococcosis is the most common opportunistic fungal infection in people with human immunodeficiency virus. On a global scale, it causes 15% of acquired immunodeficiency syndrome-related mortality. Case Summary: We report the case of a 21-year-old cisgender pregnant woman living with human immunodeficiency virus who presented with headache and photophobia. Her clinical course was complicated by recurrent hospital admissions for disseminated cryptococcosis and a life-threatening reaction to liposomal amphotericin B, the mainstay of treatment. A desensitization protocol was implemented, allowing for continuation of therapy during pregnancy. Conclusion: The management of cryptococcosis in pregnancy is challenging due to the potential teratogenic effects of antifungals used and the limited therapeutic options available. This case highlights the complexities of treatment in pregnancy and demonstrates successful desensitization to liposomal amphotericin B during pregnancy.

  • Top Cited Papers
    Open Access

    Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults

    by Zachary Nelson, Abdullah Tarık Aslan, Nathan P. Beahm, Michelle Blyth, Matthew Cappiello, Danielle Casaus, Fernando Dominguez, Susan Egbert, Alexandra Hanretty, Tina Khadem, et al.

    Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.


  • Open Access

    Effectiveness of oral vancomycin as prophylaxis against Clostridioides difficile infection in hematopoietic stem cell transplant patients

    by Kelly M. Reitmeyer, Brijesh Rana, David Awad, Esther Huang, Jiyeon J. Park, Arsheena Yassin, John P. Mills, Ahmed Abdul Azim, Pinki J. Bhatt, Navaneeth Narayanan

    Objective: Patients receiving hematopoietic stem cell transplants (HSCT) are at increased risk for Clostridioides difficile infection (CDI). The purpose of this study was to assess the effectiveness of oral vancomycin prophylaxis (OVP) for CDI in HSCT patients. Design: Single-center, retrospective cohort. Setting: Tertiary care academic medical center in New Jersey. Patients: Patients ≥18 years old during admission for the HSCT were included. Patients who were admitted P = .0147). There were no significant (P > .05) between-group differences in incidence of gram-negative bloodstream infections, hospital survival, and length of stay. There were zero clinical cultures positive for VRE. Conclusions: In-hospital incidence of CDI in HSCT patients was significantly decreased with OVP. Randomized controlled trials are needed in this high-risk population to assess the efficacy and risks of OVP for CDI.


  • Open Access

    1371. Identification of Risk Factors to Predict Gram negative bacteria in Patients with Upper Extremity Infections

    by Sophia Zhitomirsky, Hendrik Sy, Arsheena Yassin, Christine Stavropoulos, Andras Farkas

    Gram negative bacteria (GNB) have been identified as a cause of upper extremity infections and empiric treatment directed to both gram positive and negative organisms is often recommended. Risk-based approaches to establish need for gram-negative coverage may help to minimize unnecessary drug exposure, but further information on such methods are currently lacking. The aim of this study was to identify risk factors associated with the isolation of GNB in patients with upper extremity infections. We reviewed records of patients with upper extremity infections treated in two urban hospitals between March 2018 and July 2020. Prosthetic joint infections were excluded. Baseline demographic, clinical, surgical and microbiology data was collected. Multivariable logistic regression models were screened using Akaike Information Criterion to establish the best model and risk factors associated with isolation of a GNB. We identified 111 patients, the majority of whom were male with frequent history of IV drug use. Deep wound cultures in 30 (33.3%) individuals yielded a GNB, and 80% of these cases were polymicrobial. Among the GNB, most prevalent were Enterobacterales (10.4%), HACEK group (6.39%), and Pseudomonas spp. (4.5%) (Tables 1. and 2.). Infections were mostly limited to the soft tissue structures of the hand and the forearm, with involvements of the joint and bone being second and third most common. The final model identified the use of IV medications (OR 4.14, 95% CI 1.3 - 14.46) together with prior surgery at the site of infection within the last year (OR 5.56, 95% CI 1.06 - 30.98), and having an open wound on presentation (OR 3.03, 95% CI 1.04 - 9.47) as factors independently associated with isolation of a GNB (Table 3). AUROC of 0.702 indicates acceptable model discrimination. Table 1: Baseline characteristics Table 2: Bacterial isolates Table 3: Final model Our logistic regression model identified significant predictors for isolation of GNB in upper extremity infections within this population. Results of this study will assist clinicians in making a better informed decision for the need of empiric gram negative coverage aimed to support the reduction of patient exposure to unnecessary antimicrobial coverage. External validation of the model is warranted prior to application to clinical care. Figure 1: AUROC All Authors: No reported disclosures

  • Open Access

    1255. External Validation and Systematic Quantification of the Predictive Performance of Carbapenem Resistant Enterobacterales Risk Prediction Models in Hospitalized Patients

    by Andras Farkas, Arsheena Yassin, Hendrik Sy, Kristy Huang, Iana Stein, Samuel Acquah, Sara Radparvar, Christine Stavropoulos, Joseph Mathew

    Accurately predicting the presence of a carbapenem resistant enterobacterales (CRE) in hospitalized patients presents itself as an opportunity that would support timely initiation of CRE active agents. The aim of this study is to determine how reliably the existing risk prediction models identify patients likely to require empiric anti-CRE treatment, preliminary results of which are presented herein. A systematic search identified all existing CRE prediction models for validation in our patient population. Medical records of hospitalized patients within the Mount Sinai Health System in New York were subsequently reviewed. Data was gathered on model predictors, baseline demographics, clinical information, microbiology results, antibiotic utilization history and index infection. Besides calculating the AUROC, the main outcome of our study was to establish optimal prediction score cutoffs and false positive rates (FPR) where corresponding model performance maintains a false negative rate (FNR) of < 10%, < 20% and < 30%, respectively. 12 models were retained for validation. We identified 106 patients, 41 of which were treated for a CRE infection. Previous admission, organ transplantation, CKD, infection type, and carbapenem use were baseline variables that significantly differed between the groups treated for a CRE or non-CRE related infection (Table 1). The models ability to discriminate varied as evidenced by the AUROC range of 0.5 to 0.77 (Figure 1), suggesting the Seligmen et al. model as the overall best. When evaluated at the pre-specified FNR intervals of < 10%, < 20% and < 30%, the model by Lodise et al., Seligman et al., and Vazquez-Guillamet et al. produced the best FPR, respectively (Table 2). Table 1. Baseline characchteristics Table 2. Model Performance Figure 1. AUROCs Discriminative ability of the risk prediction models showed varying performance. The model by Lodise et al. appears to be most useful when a low risk level is deemed acceptable for failure rate, while at a moderate to high risk of missing a CRE case (20% and 30% FNR), the methods by Seligman and Vazquez-Guillamet et al. are most desirable as they minimize the chance of over-treatment. Additional work to increase sample size and to evaluate the models inter-rater reliability is currently on going. All Authors: No reported disclosures

  • Open Access

    Rates of Clostridioides difficile at an Urban Hospital During Initial COVID Pandemic Wave

    by Barbara A. Smith, Kilyoub Kim, Arsheena Yassin, Bernard Camins, Lindsey Gottlieb